The most recent international documents on the management and therapy of chronic
obstructive pulmonary disease (COPD) recommend inhaled corticosteroids (ICS) in addition …

Background The present study aimed to explore the mechanism of the modified Bushen Yiqi
formula (MBYF) in the treatment of chronic obstructive pulmonary disease (COPD) based on …

Drugs for chronic obstructive pulmonary disease - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …

BACKGROUND Chronic obstructive pulmonary disease (COPD) is the most common
smoking-related illness. COPD often is underemphasized as a comorbidity except when …

The purpose of this study was to systematically review the efficacy and safety of long-acting
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …

Inhaled corticosteroids (ICS) are often prescribed for worsening breathlessness,
exacerbation frequency or lung function in chronic obstructive pulmonary disease (COPD) …

Treatment of acute exacerbations involves prompt administration of antibiotic therapy with
usually 14 days of oral, or for severe exacerbations, intravenous antibiotics. The role of …

Background: Pulmonary conditions such as asthma and chronic obstructive pulmonary
disease (COPD) are common conditions that warrant special consideration in the …

Exacerbations, which often lead to emergency department visits and hospitalizations, are
the main drivers of morbidity and utilization of health care resources among patients with …

Approximately 12 million adults in the United States receive a diagnosis of chronic
obstructive pulmonary disease (COPD) each year, and it is the fourth leading cause of …